Oral targeted protein degraders have attracted the attention of innovators looking to exploit their differentiated mechanism of action, which routes target disease-related proteins to the ubiquitin proteasome system for degradation. This approach, which can be used to address both existing and undruggable targets, has resulted in a growing portfolio of protein degraders in development. However, due to their molecular complexity, a rational drug design approach is challenging, resulting in novel drug discovery hurdles and many molecules with limited to no prospect of becoming oral drug candidates.
In this webinar, experts will review the trends and challenges associated with the rational design of targeted protein degrader drugs. This will be followed by a discussion on the developability assessment of this class of molecules that leverage novel models to account for, and serve to predict, their oral bioavailability. In addition, experts will share perspectives on how to inform the selection and development of orally bioavailable drugs, and CMC approaches to efficiently develop and manufacture targeted protein degraders.
Audience – who should attend?
In his role at Catalent, Mr. Meissonnier leads new product development, providing customers with scientific advice when initiating a relationship and later, in developing their programs. He also heads Catalent’s technology innovation strategies and efforts across existing and emerging therapeutic modalities, helping Catalent achieve its mission to develop, manufacture and supply products that help people live better, healthier lives. He oversees Catalent’s scientific community, which has more than 3,000 scientists, engineers, and technicians, united in their aim to accelerate life science innovation. He currently serves as a board member for Polepharma, the French biopharmaceutical industry and manufacturing association, and holds an engineering degree in physico-chemistry and material science from the ENSI in Caen, France.
Giulia Caron received a B.Sc. in Pharmaceutical Chemistry and Technology at the University of Turin (Italy). She then moved to the University of Lausanne (Switzerland) where was awarded a Ph.D. in Pharmaceutical Sciences in 1997 under the supervision of prof. B. Testa. She holds the position of Associate Professor at the Molecular Biotechnology and Health Sciences Department at the University of Turin and teaches medicinal chemistry and drug discovery. Her primary scientific interest is the design, experimental determination and computational prediction of physicochemical and in vitro ADME properties of drugs and drug candidates in the bRo5 chemical space (PROTACs and macrocycles among others).
Nathan Bennette is Director, Scientific Advisory in Catalent’s global Science and Technology group and a member of Catalent’s small molecule advisory team for North America. In this capacity he works directly with partners to understand the key drug delivery objectives for their specific molecule, collaborate on the target product profile and define a strategy for the development program. He has over 13 years of experience in pharmaceutical development and delivery with an emphasis in bioavailability enhancement. Bennette is particularly interested in the application of the scientific method early in the design and development process along with improving clinical outcomes by bringing a ‘right-first-time’ approach to formulation and process design. He holds a master’s in Inorganic and Organometallic Chemistry from the University of Washington.
Stephen Tindal is the Director of Science and Technology at Catalent. His work is largely focused on preclinical to phase 1 development and is based on assessing preclinical data to help define any challenges to dosage form development. Tindal has more than 36 years' experience at Catalent, where he has held roles of increasing responsibility and has demonstrated expertise in root cause investigation, technology innovation and supporting business development. He holds a bachelor’s degree in Chemistry and Analytical Science from Loughborough University, Loughborough, U.K.
Jan Neelissen has 20 years of industry experience in the field of DMPK, of which 17 years at AstraZeneca holding positions as Associate Principle Scientist delivering 7 clinical drug candidates, Associate Director in vitro DMPK, and Associate Director Modeling and Simulation. Dr. Neelissen is a biologist by training and received his doctoral degree from the University of Leiden, Netherlands.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.